[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric-bronchiolitis-obliterans\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric-bronchiolitis-obliterans":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100611385","early-phase-1-treatment-of-pediatric-bronchiolitis-obliterans-by-airway-basal-stem-cells-100611385",false,"NCT07239895","Treatment of Pediatric Bronchiolitis Obliterans by Airway Basal Stem Cells","Exploratory Study of Airway Basal Stem Cells on Treatment of Pediatric Bronchiolitis Obliterans","Inclusion Criteria:\n\n* Males and females, aged between 28 days and 18 years;\n* Diagnosed with bronchiolitis obliterans according to the guidelines;\n* Meeting at least one of the following: FEV1 \\\u003C 55% of predicted value; requiring continuous assisted mechanical ventilation or oxygen therapy;\n* None of acute infections within the past four weeks;\n* Tolerating bronchoscopy;\n* The child and\u002For parent(s) provide informed consent, and are able to understand and adhere to scheduled visits, treatments, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* Subjects with bronchiolitis obliterans syndrome (BOS) who are on a current cGVHD treatment regimen at screening.\n* At the time of screening, subject who is positive in each of treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody test. Hepatitis B virus carriers with stable current condition can be enrolled. Cured hepatitis C patients with negative result in HCV ribonucleic acid (RNA) test can be enrolled as well.\n* Subject who is assessed to have major lung diseases other than BO by investigators at screening or who has other severe systemic diseases within 6 months prior to screening and is considered to be unsuitable for this study by investigators.\n* Presence of severe coagulation dysfunction at screening and may compromise the safety of bronchoscopy in the investigator's judgment.\n* Subjects requiring long-term maintenance anticoagulant therapy or antiplatelet aggregation therapy, and for whom, in the investigator's assessment, the medication cannot be discontinued within a week prior to cell collection and infusion.\n* Subjects with suicide risk or a history of psychiatric disorders at screening.\n* Participation in another interventional clinical study within 3 months prior to screening.\n* Poor compliance, making him or her difficult to complete the study.\n* Subjects who is considered to be unsuitable for this study in in the opinion of the investigator.","ALL","28 Days","18 Years",{"count":20,"type":21},12,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","Bronchiolitis obliterans (BO) is a chronic lung disease which was initiated with injury of the bronchiolar epithelium and resulted in nonuniform luminal obliteration or narrowing. Among children, the most common form of BO is post-infectious BO with a lack of treatment guidelines or standard therapy. In this study, an open, single-armed study is performed to preliminarily evaluate the safety and efficacy of airway basal stem cells on treatment of pediatric BO.",[27],"Pediatric Bronchiolitis Obliterans",[29,30,31,32],"Airway Basal Stem Cells","Bronchiolitis obliterans","Bronchiolar Epithelium","Pedatric Bronchiolitis Obliterans","RECRUITING","2026-01-12",{"date":36,"type":37},"2026-01-14","ACTUAL",{"date":39,"type":37},"2025-11-11",{"date":41,"type":21},"2027-11",{"name":43,"class":44},"Regend Therapeutics","INDUSTRY"]